Navigation Links
Halozyme Therapeutics to Host Research Day for Investors and Analysts
Date:10/1/2008

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a Research Day on Wednesday, October 8, beginning at 12:15 p.m. EDT. A webcast of the presentations will be available live on the company website.

PRESENTATIONS

-- Strategic Company Overview, Jonathan Lim, M.D., President and Chief Executive Officer

-- Science and Technology Overview, Gregory Frost, Ph.D., Vice President and Chief Scientific Officer

-- Insulins -- Faster Acting, Regular and Analog, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- Bisphosphonates -- Advantages of Subcutaneous Injection with rHuPH20, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- PEGPH20 -- A Targeted Therapy for Cancer Treatment, Patrick O'Connor, Ph.D., Vice President, Research

-- Chemophase -- Next Steps to Pivotal Trials, Richard C. Yocum, M.D., Vice President, Clinical Development and Medical Affairs

-- Commercial Opportunities -- The Value Proposition, Robert L. Little, Vice President and Chief Commercial Officer

Halozyme will conduct a live webcast of the presentations beginning at 12:15 p.m. EDT. To access the webcast over the internet, please go to the company website at http://www.halozyme.com. An archive of the presentation will be available on Halozyme's website shortly after the conclusion of the meeting.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Mentus

Investor Relations (858) 455-5500, x275/x215

(858) 704-8264 karen@mentus.com

ruhl@halozyme.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
6. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... published evaluation of multiple immunoassay-based threat detection technologies by researchers from the ... CANARY® biosensor threat detection technology was found to have the best level ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The Greater ... a new partnership with Compass Research . GGI's mission is to advance global ... to a child in need in honor of each clinical trial volunteer. The vision ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
Breaking Biology News(10 mins):